Cognition Therapeutics
CGTX
66 hedge funds and large institutions have $26M invested in Cognition Therapeutics in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 13 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
124% more capital inflows, than outflows
Capital inflows: $3.1M | Capital outflows: $1.39M
1.27% more ownership
Funds ownership: 23.97% → 25.24% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 75 → 66 (-9)
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Davenport & Co
Richmond,
Virginia
|
+$1.62M |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$517K |
| 3 |
BlackRock
New York
|
+$348K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$168K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$502K |
| 2 |
Jane Street
New York
|
-$281K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$139K |
| 4 |
HF
HRT Financial
New York
|
-$116K |
| 5 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$70.2K |
CGTX Hedge Fund Activity: Q2 2026 in Review
66 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q2 2026, worth a combined $26M — up 60% from $16.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CGTX and 4 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 23 added.
The largest buyer was Davenport & Co, adding an estimated $1.62M. The largest seller was Renaissance Technologies, cutting an estimated $502K.
- 66 institutional investors held Cognition Therapeutics (CGTX) as of Q2 2026, down from 75 in Q1 2026.
- Funds reported $26M of Cognition Therapeutics stock for Q2 2026, up 60% quarter-over-quarter.
- 4 funds opened new Cognition Therapeutics positions in Q2 2026 and 13 closed out, a net change of -9 holders.
- The largest Cognition Therapeutics buyer in Q2 2026 was Davenport & Co, an estimated $1.62M added.
- The largest Cognition Therapeutics seller in Q2 2026 was Renaissance Technologies, an estimated $502K sold.
Based on aggregated 13F filings for Q2 2026.